Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Strong Cash Position at exit 2020

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Nov 16, 2020 11:00am

871 Views

Post# 31906392

Strong Cash Position at exit 2020

Cipher had cash of $4.7 m US at exit Q3.
Cipher also had Receivables in excess of Payables by $5 m US.

Q4 is the strongest quarter of the year.
The first three quarters generated on average $2 m US in free cash flows.
Q4 should have free cash flows of about $3 m US

Those excess $5 m in Receivables will be fully paid by exit 2020

So, we have $4.7 m cash to start with plus $5 m coming in from Q3 Receivables along with $3 m in Q4 cash flows for a total cash position of $12.7 m US which is about $18 m in CAD or about $0.65 per share in cash..

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec